Login to Your Account



Boehringer Ingelheim Terminates MIV-310 Plans; Medivir Shares Fall

By Cormac Sheridan


Wednesday, March 16, 2005
Shares in Medivir AB dropped by 21.25 percent Tuesday on news that partner Boehringer Ingelheim GmbH opted to discontinue development of the HIV drug MIV-310 (alovudine) following a Phase IIa trial in which the compound failed to attain a target efficacy level. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription